BioSpace News Archive

United Spinal Association announced Vincenzo Piscopo, an experienced professional in diversity, inclusion and social causes, has been appointed president and CEO by the organization’s board of directors.

GenomOncology announced the release of their newest product, igniteIQ. igniteIQ is a solution designed to efficiently extract clinically-relevant data from scanned or digital PDF reports, currently NGS and pathology reports, and convert that data to discrete data elements.

IVX Health, a national provider of infusion and injection therapy for patients with multiple sclerosis, Crohn’s disease, ulcerative colitis, and other complex chronic conditions, today announced the opening of two new centers in the Chicago metropolitan area.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020.

Alzheimer’s Breakthrough: C 2 N First to Offer a Widely Accessible Blood Test PrecivityAD TM Blood Test Answers Calls from Patients, Advocates, and Physicians Who Want Earlier Answers

enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients with cystic fibrosis (CF).

Providence, one of the largest health systems in the country, today announced that Sylvain “Syl” Trepanier, D.N.P., R.N., will serve as the organization’s new system-wide chief nursing officer (CNO), effective January 1, 2021.

- Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] - The cobas EGFR Mutation Test v2 is FDA approved as a companion diagnostic for the detection of EGFR mutations in NSCLC for both tissue and plasma samples, with results available in less than eight hours[2] - The new FDA approval allows the test to be used as a companion diagnostic for a broad group of EGFR TKI therapies

Alzheimer’s Drug Discovery Foundation’s Funding Played Instrumental Role in Helping C2N Diagnostics Develop Test

Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data from its multi-targeted antibody therapy enhancer (MATE™) conjugation platform at the upcoming Society for Immunotherapy of Cancer’s (SITC) 35 th Annual Meeting. The meeting is taking place in a virtual format from November 9-14, 2020. Details of the p